FDA Pushes uniQure Huntington Therapy Forward, Analyst Brushes Off Softening Signals
FDA grants Priority Review to uniQure for its Huntington's gene therapy, setting a PDUFA target date of May 1, 2027.
Share
Why It Matters
The FDA gave uniQure's Huntington's treatment a fast track review. This means the agency thinks it could help sick people soon.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.